EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alkermes's enterprise value is $3,669 Mil.
Alkermes's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,663 Mil. Therefore, Alkermes's EV-to-Revenue for today is 2.21.
The historical rank and industry rank for Alkermes's EV-to-Revenue or its related term are showing as below:
ALKS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.47 Med: 5.16 Max: 17.36
Current: 2.21
During the past 13 years, the highest EV-to-Revenue of Alkermes was 17.36. The lowest was 1.47. And the median was 5.16.
ALKS's EV-to-Revenue is ranked better than 51.85% of 1026
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs ALKS: 2.21
As of today (2024-04-23), Alkermes's stock price is $24.26.
Alkermes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.82. Therefore, Alkermes's PS Ratio for today is 2.47.
Alkermes EV-to-Revenue Historical Data
The historical data trend for Alkermes's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes EV-to-Revenue Distribution
For the Drug Manufacturers industry and Healthcare sector, Alkermes's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alkermes's EV-to-Revenue falls into.
Alkermes's current Enterprise Value is $3,669 Mil.
Alkermes's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,663 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes's share price for today is $24.26.
Alkermes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alkermes's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALKS has been successfully added to your 